Poland's AI medical technology corporations Medicalgorithmics is accelerating its push into the global market, proving its electrocardiogram (ECG) analysis capabilities.
The global journal Nature Medicine recently published study results showing that the company's AI algorithm "DRAI" reduced serious arrhythmia diagnosis errors by 14 times compared with conventional clinical methods.
On the 19th at the EU Business Hub of KIMES 2026 at COEX in Seoul, Business Development Manager Kamil Kryscio, who met with ChosunBiz, said, "Medical professionals trust only data," and emphasized, "Data proven through independent research has made us a game changer in the market."
◇ Misdiagnosis rate 4.4% vs. 0.3%…"AI's victory" recognized by Nature
The results were striking from an analysis by Lund University in Sweden and the Population Health Research Institute (PHRI) in Canada of ECG data from 14,606 patients over 200,000 days. The rate at which a skilled electrocardiography technician missed serious arrhythmias was 4.4%, but DRAI's was just 0.3%. In particular, the reliability of determining the absence of arrhythmia in 14-day long-term data reached 99.9%.
Professor Linda Johnson, who led the research, said, "With a global shortage of 15 million health care workers, a system in which AI replaces skilled technicians and delivers reports directly to doctors is an innovation that can resolve medical bottlenecks." Kryscio noted, "The essence of our technology is securing the golden time by dramatically accelerating decision-making."
Medicalgorithmics' purpose for this visit to Korea is to build "third-party integration" partnerships. The strategy is to implant its AI software and cloud platform "DRP" into Korean corporations with strong hardware.
Tangible results are following. A representative case is Wellisys, a startup spun off from Samsung SDS. The two sides formed a strategic partnership last year and entered the U.S. market by integrating Medicalgorithmics' AI algorithm into Wellisys' wearable ECG device "S-Patch."
Kryscio said, "We can be the answer for corporations with excellent devices that struggle to secure U.S. Food and Drug Administration (FDA)-approved software."
◇ From Peru to Japan, "territory expansion"…"Targeting Asia with 20 years of data"
Medicalgorithmics is taking an aggressive approach, signing more than 20 global contracts last year alone.
As a next-generation growth engine, it has put forward its coronary blood flow analysis solution "VCAST." The technology assesses a patient's condition through CT-based 3D mapping instead of conventional invasive angiography. It is aiming to enter the U.S. market in the second half of next year.
Kryscio said, "We will raise our U.S. ECG market share, currently around 3%, by at least twofold," adding, "We have taken our first step into the South American market with a recent contract in Peru, and after this visit to Korea, we plan to start targeting the Japanese market through an event in Osaka in July."
Kryscio also suggested that the company's solutions could be an answer to Korea's rapid aging problem. "Diagnostic backlogs in major cities and reduced medical access for older adults in rural areas are global challenges," Kryscio said. "A remote diagnostic system in which patients measure at home and doctors anywhere in the world review AI reports will narrow medical gaps."
Medicalgorithmics issued 500,000 AI reports last year and is aiming to reach 1 million this year. Kryscio emphasized, "As a listed company with 20 years of experience, we will lead medical innovation in the Asian market based on our accumulated data and regulatory response capabilities."